China Resources Double-Crane Pharmaceutical Co Ltd (600062) - Total Liabilities

Latest as of September 2025: CN¥4.85 Billion CNY ≈ $710.14 Million USD

Based on the latest financial reports, China Resources Double-Crane Pharmaceutical Co Ltd (600062) has total liabilities worth CN¥4.85 Billion CNY (≈ $710.14 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 600062 shareholders equity momentum to track the company's year-over-year net asset growth rate.

China Resources Double-Crane Pharmaceutical Co Ltd - Total Liabilities Trend (1994–2024)

This chart illustrates how China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600062 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

China Resources Double-Crane Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of China Resources Double-Crane Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
BB Biotech AG SW:BION	Switzerland	CHF7.86 Million
Artois Nom. PA:ARTO	France	€117.83 Million
Banque Cantonale du Valais SW:WKBN	Switzerland	CHF20.33 Billion
Lucid Group Inc NASDAQ:LCID	USA	$5.45 Billion
Ideaya Biosciences Inc NASDAQ:IDYA	USA	$93.08 Million
Kaori Heat Treatment Co Ltd TW:8996	Taiwan	NT$3.25 Billion
EO Technics Co. Ltd KQ:039030	Korea	₩96.55 Billion
Zhejiang Yongtai Technology Co Ltd SHE:002326	China	CN¥8.21 Billion

Liability Composition Analysis (1994–2024)

This chart breaks down China Resources Double-Crane Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see China Resources Double-Crane Pharmaceuti (600062) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	2.25	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.43	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.29	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how China Resources Double-Crane Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for China Resources Double-Crane Pharmaceutical Co Ltd (1994–2024)

The table below shows the annual total liabilities of China Resources Double-Crane Pharmaceutical Co Ltd from 1994 to 2024.

Year	Total Liabilities	Change
2024-12-31	CN¥5.57 Billion ≈ $815.69 Million	+53.09%
2023-12-31	CN¥3.64 Billion ≈ $532.82 Million	-2.98%
2022-12-31	CN¥3.75 Billion ≈ $549.17 Million	+17.30%
2021-12-31	CN¥3.20 Billion ≈ $468.19 Million	+5.26%
2020-12-31	CN¥3.04 Billion ≈ $444.77 Million	+16.89%
2019-12-31	CN¥2.60 Billion ≈ $380.51 Million	+8.46%
2018-12-31	CN¥2.40 Billion ≈ $350.84 Million	+50.85%
2017-12-31	CN¥1.59 Billion ≈ $232.57 Million	+32.11%
2016-12-31	CN¥1.20 Billion ≈ $176.04 Million	-9.49%
2015-12-31	CN¥1.33 Billion ≈ $194.50 Million	+42.17%
2014-12-31	CN¥934.93 Million ≈ $136.81 Million	-18.32%
2013-12-31	CN¥1.14 Billion ≈ $167.50 Million	-36.44%
2012-12-31	CN¥1.80 Billion ≈ $263.55 Million	+3.89%
2011-12-31	CN¥1.73 Billion ≈ $253.69 Million	+35.49%
2010-12-31	CN¥1.28 Billion ≈ $187.24 Million	+8.24%
2009-12-31	CN¥1.18 Billion ≈ $172.99 Million	+5.69%
2008-12-31	CN¥1.12 Billion ≈ $163.68 Million	-14.53%
2007-12-31	CN¥1.31 Billion ≈ $191.52 Million	+3.53%
2006-12-31	CN¥1.26 Billion ≈ $184.98 Million	-32.55%
2005-12-31	CN¥1.87 Billion ≈ $274.23 Million	-18.45%
2004-12-31	CN¥2.30 Billion ≈ $336.26 Million	-9.57%
2003-12-31	CN¥2.54 Billion ≈ $371.86 Million	+26.33%
2002-12-31	CN¥2.01 Billion ≈ $294.35 Million	+60.12%
2001-12-31	CN¥1.26 Billion ≈ $183.83 Million	+99.76%
2000-12-31	CN¥628.89 Million ≈ $92.03 Million	+32.79%
1999-12-31	CN¥473.60 Million ≈ $69.30 Million	+137.31%
1998-12-31	CN¥199.57 Million ≈ $29.20 Million	+96.08%
1997-12-31	CN¥101.78 Million ≈ $14.89 Million	+109.89%
1996-12-31	CN¥48.49 Million ≈ $7.10 Million	+66.25%
1995-12-31	CN¥29.17 Million ≈ $4.27 Million	-19.92%
1994-12-31	CN¥36.42 Million ≈ $5.33 Million	--

About China Resources Double-Crane Pharmaceutical Co Ltd

SHG:600062 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.47 Billion

CN¥16.90 Billion CNY

Market Cap Rank

#5404 Global

#945 in China

Share Price

CN¥16.27

Change (1 day)

+0.25%

52-Week Range

CN¥15.60 - CN¥20.62

All Time High

CN¥33.06